$2.04 Billion is the total value of Camber Capital Management LP's 32 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 58.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SHPG | New | SHIRE PLCsponsored adr | $164,329,000 | – | 1,100,000 | +100.0% | 8.07% | – |
| NKTR | Sell | NEKTAR THERAPEUTICS | $159,390,000 | -20.3% | 1,500,000 | -55.2% | 7.82% | -20.1% |
| AGN | Buy | ALLERGAN PLC | $143,047,000 | +45.7% | 850,000 | +41.7% | 7.02% | +46.2% |
| BIIB | New | BIOGEN INC | $141,017,000 | – | 515,000 | +100.0% | 6.92% | – |
| HCA | HCA HEALTHCARE INC | $121,250,000 | +10.4% | 1,250,000 | 0.0% | 5.95% | +10.8% | |
| EVHC | Buy | ENVISION HEALTHCARE CORP | $109,526,000 | +26.8% | 2,850,000 | +14.0% | 5.38% | +27.1% |
| THC | Sell | TENET HEALTHCARE CORP | $103,063,000 | +18.2% | 4,250,000 | -26.1% | 5.06% | +18.6% |
| TSRO | Buy | TESARO INC | $98,567,000 | +39.9% | 1,725,000 | +102.9% | 4.84% | +40.3% |
| UHS | UNIVERSAL HLTH SVCS INCcl b | $92,360,000 | +4.5% | 780,000 | 0.0% | 4.54% | +4.8% | |
| BMY | New | BRISTOL MYERS SQUIBB CO | $79,063,000 | – | 1,250,000 | +100.0% | 3.88% | – |
| GHDX | GENOMIC HEALTH INC | $76,914,000 | -8.5% | 2,458,100 | 0.0% | 3.78% | -8.2% | |
| MDCO | Buy | MEDICINES CO | $65,880,000 | +50.6% | 2,000,000 | +25.0% | 3.23% | +51.1% |
| ATRA | Buy | ATARA BIOTHERAPEUTICS INC | $63,051,000 | +550.5% | 1,616,690 | +201.9% | 3.10% | +553.2% |
| NUVA | New | NUVASIVE INC | $62,652,000 | – | 1,200,000 | +100.0% | 3.08% | – |
| GSK | GLAXOSMITHKLINE PLCsponsored adr | $58,605,000 | +10.1% | 1,500,000 | 0.0% | 2.88% | +10.5% | |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS INC | $57,960,000 | +84.1% | 1,200,000 | +50.0% | 2.85% | +84.7% |
| AMAG | AMAG PHARMACEUTICALS INC | $53,398,000 | +52.1% | 2,650,000 | 0.0% | 2.62% | +52.5% | |
| MYL | Sell | MYLAN N V | $51,463,000 | -51.3% | 1,250,000 | -50.0% | 2.53% | -51.2% |
| MYGN | MYRIAD GENETICS INC | $44,325,000 | -14.0% | 1,500,000 | 0.0% | 2.18% | -13.7% | |
| BKD | BROOKDALE SENIOR LIVING | $43,615,000 | -30.8% | 6,500,000 | 0.0% | 2.14% | -30.6% | |
| CLVS | Buy | CLOVIS ONCOLOGY INC | $43,560,000 | +6.8% | 825,000 | +37.5% | 2.14% | +7.1% |
| ELGX | Buy | ENDOLOGIX INC | $39,339,000 | -8.1% | 9,300,000 | +16.2% | 1.93% | -7.8% |
| PRGO | New | PERRIGO CO PLC | $33,336,000 | – | 400,000 | +100.0% | 1.64% | – |
| CSII | New | CARDIOVASCULAR SYS INC DEL | $27,113,000 | – | 1,236,360 | +100.0% | 1.33% | – |
| KTWO | Buy | K2M GROUP HLDGS INC | $25,570,000 | +67.1% | 1,349,323 | +58.7% | 1.26% | +67.6% |
| VRX | New | VALEANT PHARMACEUTICALS INTL | $23,880,000 | – | 1,500,000 | +100.0% | 1.17% | – |
| WMGI | Buy | WRIGHT MED GROUP N V | $16,170,000 | +26.7% | 815,000 | +41.7% | 0.79% | +27.0% |
| ENDP | New | ENDO INTL PLC | $14,850,000 | – | 2,500,000 | +100.0% | 0.73% | – |
| DRNA | DICERNA PHARMACEUTICALS INC | $9,560,000 | +5.9% | 1,000,000 | 0.0% | 0.47% | +6.1% | |
| PRTA | Buy | PROTHENA CORP PLC | $9,178,000 | +95.9% | 250,000 | +100.0% | 0.45% | +96.9% |
| MNTA | New | MOMENTA PHARMACEUTICALS INC | $2,456,000 | – | 135,300 | +100.0% | 0.12% | – |
| SGRY | SURGERY PARTNERS INC | $2,317,000 | +41.7% | 135,084 | 0.0% | 0.11% | +42.5% | |
| MNKKQ | Exit | MALLINCKRODT PUB LTD CO | $0 | – | -105,000 | -100.0% | -0.12% | – |
| BIOS | Exit | BIOSCRIP INC | $0 | – | -2,540,200 | -100.0% | -0.36% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -300,000 | -100.0% | -0.82% | – |
| NVTA | Exit | INVITAE CORP | $0 | – | -2,398,123 | -100.0% | -1.07% | – |
| ALKS | Exit | ALKERMES PLC | $0 | – | -400,000 | -100.0% | -1.07% | – |
| OFIX | Exit | ORTHOFIX INTL N V | $0 | – | -500,000 | -100.0% | -1.34% | – |
| RDUS | Exit | RADIUS HEALTH INC | $0 | – | -1,000,000 | -100.0% | -1.56% | – |
| EXAS | Exit | EXACT SCIENCES CORPput | $0 | – | -1,000,000 | -100.0% | -2.57% | – |
| TEVA | Exit | TEVA PHARMACEUTICAL INDS LTDcall | $0 | – | -3,000,000 | -100.0% | -2.78% | – |
| BIVV | Exit | BIOVERATIV INC | $0 | – | -1,096,000 | -100.0% | -2.89% | – |
| SPY | Exit | SPDR S&P 500 ETF Trustput | $0 | – | -1,500,000 | -100.0% | -19.59% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.